Jocelyn Qi-Min Teo, Hong Yi Chang, Si Hui Tan, Cheng Yee Tang, Rick Twee-Hee Ong, Karrie Kwan Ki Ko, Shimin Jasmine Chung, Thuan Tong Tan, Andrea Lay-Hoon Kwa
Limited treatment options exist for the treatment of carbapenem-resistant Enterobacterales (CRE) bacteria. Fortunately, there are several recently approved antibiotics indicated for CRE infections. Here, we examine the in vitro activity of various novel agents (eravacycline, plazomicin, ceftazidime-avibactam, imipenem-relebactam, and meropenem-vaborbactam) and comparators (tigecycline, amikacin, levofloxacin, fosfomycin, polymyxin B) against 365 well-characterized CRE clinical isolates with various genotypes...
June 15, 2023: Microbiology Spectrum